GSK receives CHMP positive opinion recommending approval of Zejula (niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer
This opinion follows the expansion of Zejula’s indication in the US with approval by the US Food and Drug Administration earlier this year.
